Evidence map›Paper›PMID 39503370›Full record

ArticleNeuro-oncology2025

Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective study.

Alexander P Landry, Justin Z Wang, Vikas Patil, Chloe Gui, Yasin Mamatjan, Zeel Patel, Rebecca Yakubov, Ramneet Kaloti, Parnian Habibi, Mark Wilson and 31 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors.

Alexander P LandryPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Justin Z WangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Vikas PatilPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Chloe GuiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Yasin MamatjanPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Zeel PatelTemerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.
Rebecca YakubovPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Ramneet KalotiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Parnian HabibiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Mark WilsonTemerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.
Andrew AjisebutuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Yosef EllenbogenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Qingxia WeiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Olivia SinghPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Julio SosaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Sheila MansouriPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Christopher WilsonOklahoma State University College of Osteopathic Medicine, Tulsa, Oklahoma, USA.
Aaron A Cohen-GadolDepartment of Neurological Surgery, Keck School of Medicine, USC, Los Angeles, California, USA.
Piiamaria VirtanenDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Noah BurketDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Matthew BlackwellDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jenna KoenigDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Anthony AlfonsoDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Joseph DavisDepartment of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Mohamed A ZaazoueDepartment of Orthopedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Ghazaleh TabatabaiDepartment of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, Comprehensive Cancer Center, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.
Marcos TatagibaDepartment of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany.
Felix BehlingDepartment of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany.
Jill S Barnholtz-SloanCenter for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, Maryland, USA.
Andrew E SloanDepartment of Neurological Surgery & Piedmont Brain Tumor Center, Atlanta, Georgia, USA.
Silky ChotaiDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lola B ChamblessDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alireza MansouriDepartment of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Felix EhretGerman Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, Berlin, Germany.
David CapperCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Berlin, Germany.ORCID 0000-0003-1945-497X
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Kenneth AldapeCenter for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-5119-7550
Andrew GaoDivision of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.
International Consortium on Meningiomas (ICOM)
Farshad NassiriDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Gelareh ZadehDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6637-4502

Funding

Canadian Institutes of Health Research and Brain Tumour Charity
6 · The paper itself

Abstract

backgroundWe previously developed a DNA methylation-based risk predictor for meningioma, which has been used locally in a prospective fashion since its original publication. As a follow-up, we validate this model using a large prospective cohort and introduce a streamlined next-generation predictor compatible with newer methylation arrays.

methodsGenome-wide methylation profiles were generated with the Illumina EPICArray. The performance of our next-generation predictor was compared with our original model and standard-of-care 2021 WHO grade using time-dependent receiver operating characteristic curves. An nomogram was generated by incorporating our methylation predictor with WHO grade and the extent of resection.

resultsA total of 1347 meningioma cases were utilized in the study, including 469 prospective cases from 3 institutions and an external cohort of 100 WHO grade 2 cases for model validation. Both the original and next-generation models significantly outperform the 2021 WHO grade in predicting early postoperative recurrence. Dichotomizing patients into grade-specific risk subgroups was predictive of outcomes within both WHO grades 1 and 2 tumors (P < .05), whereas all WHO grade 3 tumors were considered high-risk. Multivariable Cox regression demonstrated the benefit of adjuvant radiotherapy (RT) in high-risk cases specifically, reinforcing its informative role in clinical decision-making. Finally, our next-generation predictor contains nearly 10-fold fewer features than the original model, allowing for targeted arrays.

conclusionsThis next-generation DNA methylation-based meningioma outcome predictor significantly outperforms the 2021 WHO grading in predicting time to recurrence. We make this available as a point-and-click tool that will improve prognostication, inform patient selection for RT, and allow for molecularly stratified clinical trials.

Indexed as

Biomarkers, TumorDNA MethylationMeningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNomogramsPrognosisProspective StudiesROC CurveBiomarkers, TumorDNA methylationmeningiomaneuro-oncologyoutcome predictionprognosis

Identifiers

PMID39503370
PMCPMC12083223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.